Boehringer touts best-in-class potential of survodutide after liver disease study data

26 Feb 2024
Phase 2Clinical ResultPhase 3
Boehringer Ingelheim announced Monday that up to 83% of adults with metabolic dysfunction-associated steatohepatitis (MASH) who were given the experimental drug survodutide achieved a significant histological improvement of their condition without worsening of fibrosis versus placebo.
The company, which is developing the glucagon/GLP-1 receptor dual agonistglucagon/GLP-1 receptor dual agonist with Zealand Pharma, suggested that on the basis of the Phase II results, the drug has the potential to a become best-in-class treatment for MASH. “We believe its true differentiator is the action of the glucagon receptor agonism which works directly on the liver,” remarked Carinne Brouillon, head of human pharma at Boehringer.
In the study, 295 adults with MASH and fibrosis, including those with and without type 2 diabetes, were randomised to receive one of three doses of survodutide or placebo. The primary endpoint is the percentage of participants achieving histological improvement of MASH without worsening of fibrosis after 48 weeks of treatment, while secondary goals include reductions in liver fat content and improvement of fibrosis.
Boehringer noted that as well as achieving the primary outcome, the trial met all secondary goals, including a significant improvement in liver fibrosis. The drugmaker indicated that full data will be presented in the coming months.
“We will move forward as quickly as possible in MASH,” Brouillon said, adding “we are also progressing with survodutide in other related conditions, having already initiated our Phase III clinical trial programme for obesity.”
More to come.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.